Tenet Healthcare Corporation (THC) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$194.51
Price Target
$268.00
Target Range
$250.00 — $288.00
Analyst Rating
Buy
Forward P/E11.0x
Trailing P/E12.6x
Forward PEG0.33
Implied Growth-8.7%
Median Target$267.50
Analyst Spread14.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$250
+28.5%
Consensus
$268
+37.8%
Bull Case
$288
+48.1%
Valuation Model TargetsConfidence: 59/100
Bear$64
Base$291
Bull$370
THC Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Tenet Healthcare Corporation (THC) has a Wall Street consensus price target of $268.00, based on estimates from 32 covering analysts. With the stock currently trading at $194.51, this represents a potential upside of +37.8%. The company has a market capitalization of $17.04B.
Analyst price targets range from a low of $250.00 to a high of $288.00, representing a 14% spread in expectations. The median target of $267.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, THC trades at a trailing P/E of 12.6x and forward P/E of 11.0x. The forward PEG ratio of 0.33 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -8.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $290.61, with bear and bull scenarios of $63.73 and $369.96 respectively. Model confidence stands at 59/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+18.0%
Avg Forward P/E20.1x
Peers with Coverage9 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HCAHCA Healthcare, Inc. | $96.0B | $429.45 | $527.45 | +22.8% | Buy | 14.2x | 46 |
 CYHCommunity Health Systems, Inc. | $404M | $2.87 | $2.93 | +2.1% | Hold | — | 37 |
 UHSUniversal Health Services, Inc. | $10.5B | $168.49 | $231.50 | +37.4% | Hold | 7.2x | 43 |
 ENSGThe Ensign Group, Inc. | $10.3B | $175.93 | $222.33 | +26.4% | Buy | 23.4x | 13 |
 SEMSelect Medical Holdings Corporation | $2.0B | $16.43 | $18.00 | +9.6% | Hold | 13.1x | 13 |
 ACHCAcadia Healthcare Company, Inc. | $2.3B | $25.30 | $23.50 | -7.1% | Buy | 17.0x | 25 |
 USPHU.S. Physical Therapy, Inc. | $1.1B | $73.61 | $102.00 | +38.6% | Buy | 25.7x | 12 |
 NHCNational HealthCare Corporation | $2.6B | $169.41 | — | — | — | 21.3x | — |
 SGRYSurgery Partners, Inc. | $1.9B | $14.59 | $18.60 | +27.5% | Buy | 38.7x | 22 |
 UNHUnitedHealth Group Incorporated | $333.4B | $367.28 | $385.43 | +4.9% | Buy | 20.1x | 52 |
Upside Potential Comparison
USPHUHSSGRYENSGHCASEMUNHCYHFull THC Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See THC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs THC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare THC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTHC — Frequently Asked Questions
Quick answers to the most common questions about buying THC stock.
What is the THC stock price target for 2026?
The consensus Wall Street price target for THC is $268, representing 37.8% upside from the current price of $194.51. With 32 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is THC a buy, sell, or hold?
THC has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $268 implies 37.8% upside from current levels.
Is THC stock overvalued or undervalued?
With a forward P/E of 10.9628x, THC trades at a relatively low valuation. The consensus target of $268 implies 37.8% appreciation, suggesting meaningful undervaluation.
How high can THC stock go?
The most bullish Wall Street analyst has a price target of $288 for THC, while the most conservative target is $250. The consensus of $268 represents the median expectation. Our quantitative valuation model projects a bull case target of $370 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover THC stock?
THC is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 7 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the THC stock forecast?
The 12-month THC stock forecast based on 32 Wall Street analysts shows a consensus price target of $268, with estimates ranging from $250 (bear case) to $288 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $291, with bear/bull scenarios of $64/$370.
What is THC's fair value based on fundamentals?
Our quantitative valuation model calculates THC's fair value at $291 (base case), with a bear case of $64 and bull case of $370. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 59/100.
What is THC's forward P/E ratio?
THC trades at a forward P/E ratio of 11.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy THC stock?
Wall Street analysts are very optimistic on THC, with a "Buy" consensus rating and $268 price target (37.8% upside). 25 of 32 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do THC price targets vary so much?
THC analyst price targets range from $250 to $288, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $268 consensus represents the middle ground. Our model's $64-$370 range provides an independent fundamental perspective.